Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APMNASDAQ:BPTHNASDAQ:CMNDNASDAQ:NCNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPMAptorum Group$0.97-3.0%$0.91$0.46▼$7.49$5.03M-0.24615,081 shs22,832 shsBPTHBio-Path$0.15-9.3%$0.16$0.12▼$4.55$1.49M0.021.26 million shs6,865 shsCMNDClearmind Medicine$1.02+4.1%$1.09$0.85▼$2.30$4.35M0.941.09 million shs77,265 shsNCNANuCana$0.55-15.4%$0.86$0.55▼$10.79$3.13M1.46435,569 shs336,838 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPMAptorum Group0.00%+16.68%+11.37%-24.81%-82.55%BPTHBio-Path0.00%-12.12%-14.71%-82.94%-94.18%CMNDClearmind Medicine0.00%-8.93%-2.86%-30.61%-15.00%NCNANuCana0.00%-36.03%-48.59%-51.32%-85.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPMAptorum Group0.8814 of 5 stars0.03.00.00.02.31.70.6BPTHBio-Path1.5463 of 5 stars3.50.00.00.00.60.01.3CMNDClearmind Medicine1.1043 of 5 stars0.05.00.00.02.41.70.0NCNANuCana3.5184 of 5 stars3.35.00.00.03.02.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPMAptorum Group 0.00N/AN/AN/ABPTHBio-Path 3.00Buy$20.0013,693.10% UpsideCMNDClearmind Medicine 0.00N/AN/AN/ANCNANuCana 2.50Moderate Buy$25.004,444.63% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPMAptorum Group$430K11.69N/AN/A$2.97 per share0.33BPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/ACMNDClearmind MedicineN/AN/AN/AN/A$0.73 per shareN/ANCNANuCanaN/AN/AN/AN/A$8.85 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPMAptorum Group-$2.83MN/A0.00∞N/AN/AN/AN/A4/28/2025 (Estimated)BPTHBio-Path-$16.08MN/A0.00N/AN/AN/A-2,842.40%-337.48%5/13/2025 (Estimated)CMNDClearmind Medicine-$5.26M-$1.22N/A∞N/AN/A-129.21%-61.15%6/12/2025 (Estimated)NCNANuCana-$34.37M-$6.55N/AN/AN/AN/A-314.47%-112.60%5/15/2025 (Estimated)Latest BPTH, NCNA, CMND, and APM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025N/ABPTHBio-Path-$0.38N/AN/AN/AN/AN/A5/15/2025N/ANCNANuCana-$0.01N/AN/AN/AN/AN/A3/20/2025Q4 2024NCNANuCana-$2.43-$0.32+$2.11-$0.32N/AN/A3/13/2025Q1 2025CMNDClearmind MedicineN/A-$0.24N/A-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPMAptorum GroupN/AN/AN/AN/AN/ABPTHBio-PathN/AN/AN/AN/AN/ACMNDClearmind MedicineN/AN/AN/AN/AN/ANCNANuCanaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPMAptorum Group0.241.16N/ABPTHBio-PathN/A0.860.86CMNDClearmind Medicine0.011.721.72NCNANuCanaN/A1.121.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPMAptorum Group3.80%BPTHBio-Path5.74%CMNDClearmind Medicine96.05%NCNANuCana44.00%Insider OwnershipCompanyInsider OwnershipAPMAptorum Group63.99%BPTHBio-Path0.72%CMNDClearmind MedicineN/ANCNANuCana31.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPMAptorum Group305.18 million1.87 millionNot OptionableBPTHBio-Path108.31 million5.73 millionOptionableCMNDClearmind MedicineN/A4.27 millionN/ANot OptionableNCNANuCana305.68 million1.82 millionNot OptionableBPTH, NCNA, CMND, and APM HeadlinesRecent News About These CompaniesNuCana plc: NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business UpdateMarch 22, 2025 | finanznachrichten.deNuCana Reports Q4 EPS GBP (1) vs. GBP (14)March 21, 2025 | markets.businessinsider.comNuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business UpdateMarch 20, 2025 | globenewswire.comNuCana Calls for Shareholder Vote on Key ResolutionsMarch 18, 2025 | tipranks.comBank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Tuesday TradingFebruary 25, 2025 | msn.comAurion Biotech Appoints Donald Munoz as Chief Financial OfficerFebruary 10, 2025 | businesswire.comEuropean Equities Traded in the US as American Depositary Receipts Fall in Monday TradingFebruary 3, 2025 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday TradingJanuary 22, 2025 | msn.comNUC-7738 by NuCana for Metastatic Melanoma: Likelihood of ApprovalJanuary 6, 2025 | pharmaceutical-technology.comNUC-7738 by NuCana for T-Cell Lymphomas: Likelihood of ApprovalDecember 30, 2024 | pharmaceutical-technology.comNUC-7738 by NuCana for Solid Tumor: Likelihood of ApprovalDecember 30, 2024 | pharmaceutical-technology.comEuropean Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Down 1.5% for WeekDecember 13, 2024 | msn.comNuCana Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 25, 2024 | globenewswire.comNuCana’s NUC-3373 Shows Promise in Cancer TreatmentNovember 13, 2024 | markets.businessinsider.comEuropean Equities Traded in the US as American Depositary Move Higher in Monday TradingNovember 12, 2024 | msn.comNuCana announces initial data from Phase 1b/2 modular study of NUC-3373November 12, 2024 | markets.businessinsider.comNuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or DocetaxelNovember 11, 2024 | globenewswire.comEuropean Equities Traded in the US as American Depositary Receipts Rise FridayOctober 18, 2024 | msn.comTruist Financial Sticks to Their Buy Rating for Nucana (NCNA)October 16, 2024 | markets.businessinsider.comBaillie Gifford's Strategic Acquisition of NuCana PLC SharesOctober 4, 2024 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBPTH, NCNA, CMND, and APM Company DescriptionsAptorum Group NASDAQ:APM$0.97 -0.03 (-3.00%) Closing price 04/25/2025 03:53 PM EasternExtended Trading$0.97 +0.00 (+0.41%) As of 04/25/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.Bio-Path NASDAQ:BPTH$0.14 -0.01 (-9.32%) As of 04/25/2025 03:56 PM EasternBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.Clearmind Medicine NASDAQ:CMND$1.02 +0.04 (+4.08%) Closing price 04/25/2025 03:55 PM EasternExtended Trading$1.00 -0.03 (-2.45%) As of 04/25/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.NuCana NASDAQ:NCNA$0.55 -0.10 (-15.37%) Closing price 04/25/2025 03:59 PM EasternExtended Trading$0.55 0.00 (-0.02%) As of 04/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
